Keyphrases
Phase II Study
100%
Acute Myeloid Leukemia
100%
Cediranib
100%
High-risk Myelodysplastic Syndrome
100%
Leukemia Risk
100%
AZD2171
100%
Myelodysplastic Syndrome
60%
Vascular Endothelial Growth Factor Receptor (VEGFR)
40%
Diarrhea
20%
Novel Therapies
20%
Anemia
20%
Flt-1
20%
Thrombocytopenia
20%
Neutropenia
20%
Partial Remission
20%
Complete Remission
20%
Dehydration
20%
Adverse Events
20%
Treatment Needs
20%
Disease Response
20%
Nausea
20%
Dyspnea
20%
Stopping Rule
20%
Accruals
20%
Receptor Tyrosine Kinase Inhibitor
20%
Therapy Options
20%
Intensive Care Medicine
20%
Hematologic Improvement
20%
Pharmacology, Toxicology and Pharmaceutical Science
Cediranib
100%
Myelodysplastic Syndrome
100%
Acute Myeloid Leukemia
100%
Remission
40%
Vasculotropin Receptor
40%
Diarrhea
20%
Protein Tyrosine Kinase Inhibitor
20%
Protein Tyrosine Kinase
20%
Adverse Event
20%
Nausea
20%
Disease
20%
Anemia
20%
Dyspnea
20%
Thrombocytopenia
20%
Neutropenia
20%